Ricardo de Godoi Mattos Ferreira

Dr. Ricardo de Godoi Mattos Ferreira

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2025 in Science
Verified
Journal Article
Closed access
KNKelly Nunes
Kelly Nunes
MSMarcos Araújo Castro e Silva
Marcos Araújo Castro e Silva
MRMaíra R. Rodrigues
Maíra R. Rodrigues
RLRenan Barbosa Lemes
Renan Barbosa Lemes
PPPatricio Pezo-Valderrama
Patricio Pezo-Valderrama
THTábita Hünemeier
Tábita Hünemeier
Brazil, the largest Latin American country, is underrepresented in genomic research despite boasting the world’s largest recently admixed population. In this study, we generated 2723 high-coverage whole-genome sequences from the Brazilian population, including urban, rural, and riverine communities representing diverse ethnic backgrounds. We reveal the impressive genomic diversity of Brazilians, identifying >8 million previously unknown variants, including 36,637 predicted deleterious and potentially affecting population health. We found a positive correlation between these deleterious variants and ancestry. Brazilian genomes are a global haplotype mosaic shaped by nonrandom mating, with peak admixture in the 18th and 19th centuries. Within this diversity, ancestry-specific haplotypes exhibit an uneven spatiotemporal distribution. We also identified putatively selected genes in this diverse population, primarily linked to fertility, immune response, and metabolic traits.

15 September 2015 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
LCLilian Cantanhêde
Lilian Cantanhêde
CJCipriano Ferreira da Silva Júnior
Cipriano Ferreira da Silva Júnior
MIMarcos Massayuki Ito
Marcos Massayuki Ito
KFKátia Paula Felipin
Kátia Paula Felipin
RNRoberto Nicolete
Roberto Nicolete
RFRicardo de Godoi Mattos Ferreira
Ricardo de Godoi Mattos Ferreira
Tegumentary Leishmaniasis (TL) is endemic in Latin America, and Brazil contributes approximately 20 thousand cases per year. The pathogenesis of TL, however, is still not fully understood. Clinical manifestations vary from cutaneous leishmaniasis (CL) to more severe outcomes, such as disseminated leishmaniasis (DL), mucosal leishmaniasis (ML) and diffuse cutaneous leishmaniasis (DCL). Many factors have been associated with the severity of the disease and the development of lesions. Recent studies have reported that the presence of Leishmania RNA virus 1 infecting Leishmania (Leishmania RNA virus 1, LRV1) is an important factor associated with the severity of ML in experimental animal models. In the present study, 156 patients who attended Rondonia's Hospital of Tropical Medicine with both leishmaniasis clinical diagnoses (109 CL; 38 ML; 5 CL+ML; 3 DL and 1 DCL) and molecular diagnoses were investigated. The clinical diagnosis were confirmed by PCR by targeting hsp70 and kDNA DNA sequences and the species causing the infection were determined by HSP70 PCR-RFPL. The presence of LVR1 was tested by RT-PCR. Five Leishmania species were detected: 121 (77.6%) samples were positive for Leishmania (Viannia) braziliensis, 18 (11.5%) were positive for Leishmania (V.) guyanensis, 3 (1.8%) for Leishmania (V.) lainsoni, 2 (1.3%) for Leishmania (Leishmania) amazonensis and 2 (1.3%) for Leishmania (V.) shawi. Six (3.9%) samples were positive for Leishmania sp. but the species could not be determined, and 4 (2.6%) samples were suggestive of mixed infection by L. (V.) braziliensis and L. (V.) guyanensis. The virus was detected in L. braziliensis (N = 54), L. guyanensis (N = 5), L. amazonensis (N = 2), L. lainsoni (N = 1) and inconclusive samples (N = 6). Patients presenting with CL+ML, DL and DCL were excluded from further analysis. Association between the presence of the virus and the disease outcome were tested among the remaining 147 patients (CL = 109 and ML = 38). Of them, 71.1% (n = 27) mucosal lesions were positive for LRV1, and 28.9% (n = 11) were negative. In cutaneous lesions, 36.7% (n = 40) were positive and 63.3% (n = 69) were negative for LRV1. The ratio P(ML|LRV1+)/P(ML|LRV1-) was 2.93 (CI95% 1.57…5.46; p<0.001), thus corroborating the hypothesis of the association between LRV1 and the occurrence of mucosal leishmaniasis, as previously described in animal models; it also indicates that LRV1 is not the only factor contributing to the disease outcome. Leishmaniasis is an infectious disease caused by protozoa of the genus Leishmania. Tegumentary Leishmaniasis (TL) is characterized by a variety of clinical forms, ranging from simple skin lesions to more severe lesions with mucosal destruction. The mechanisms by which some patients develop a severe form of the disease remain unclear. It is already known that the immune statuses of the host and parasite species are key factors influencing the clinical outcome of the disease, but is not known which are the factors that influence the parasite’s tropism to the mucosal regions. Recently, a virus found infecting Leishmania, Leishmania RNA virus 1 (LRV1), has also been reported as one important factor contributing to the disease severity. The present article reports, among 147 investigated patients from the Brazilian Western Amazon, a higher frequency of LRV1 among patients with mucosal lesions compared to patients with cutaneous lesions, statistically demonstrating that the virus is related to the worsening of the disease, increasing the risk of developing mucosal injury by almost 3 times.

21 November 2019 in Nature Communications
Verified
Journal Article
Open access
RCRenan V. H. de Carvalho
Renan V. H. de Carvalho
DLDjalma S. Lima-Junior
Djalma S. Lima-Junior
MSMarcus Vinícius G. da Silva
Marcus Vinícius G. da Silva
MDMarisa Dilucca
Marisa Dilucca
TRTamara S. Rodrigues
Tamara S. Rodrigues
DZDario S. Zamboni
Dario S. Zamboni
Leishmania RNA virus (LRV) is an important virulence factor associated with the development of mucocutaneous Leishmaniasis, a severe form of the disease. LRV-mediated disease exacerbation relies on TLR3 activation, but downstream mechanisms remain largely unexplored. Here, we combine human and mouse data to demonstrate that LRV triggers TLR3 and TRIF to induce type I IFN production, which induces autophagy. This process results in ATG5-mediated degradation of NLRP3 and ASC, thereby limiting NLRP3 inflammasome activation in macrophages. Consistent with the known restricting role of NLRP3 for Leishmania replication, the signaling pathway triggered by LRV results in increased parasite survival and disease progression. In support of this data, we find that lesions in patients infected with LRV+ Leishmania are associated with reduced inflammasome activation and the development of mucocutaneous disease. Our findings reveal the mechanisms triggered by LRV that contribute to the development of the debilitating mucocutaneous form of Leishmaniasis.

19 December 2007 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
RCRicardo Machado Cruz
Ricardo Machado Cruz
HKHenrique Krieger
Henrique Krieger
RFRicardo de Godoi Mattos Ferreira
Ricardo de Godoi Mattos Ferreira
JMJames Mah
James Mah
JHJames Hartsfield
James Hartsfield
SOSilviene Oliveira
Silviene Oliveira

1 May 2005 in American Journal of Psychiatry
Verified
Journal Article
Closed access
CGCamila Guindalini
Camila Guindalini
SSSandra Scivoletto
Sandra Scivoletto
RFRicardo de Godoi Mattos Ferreira
Ricardo de Godoi Mattos Ferreira
GBGerome Breen
Gerome Breen
MZMonica Zilberman
Monica Zilberman
MZMayana Zatz
Mayana Zatz

22 July 2015 in Brazilian Journal of Otorhinolaryngology
Verified
Journal Article
Open access
MIMarcos Massayuki Ito
Marcos Massayuki Ito
LCLilian Motta Catanhêde
Lilian Motta Catanhêde
TKTony Hiroshi Katsuragawa
Tony Hiroshi Katsuragawa
CJCipriano Ferreira da Silva Junior
Cipriano Ferreira da Silva Junior
LUÍS MARCELO ARANHA CAMARGOLUÍS MARCELO ARANHA CAMARGO
LUÍS MARCELO ARANHA CAMARGO
JVJuan Miguel Vilallobos-Salcedo
Juan Miguel Vilallobos-Salcedo
Mucosal leishmaniosis (ML) is a severe clinical form of leishmaniosis. Complex factors related to the parasite and the host are attributed to the development of mucosal lesions. Leishmania RNA virus 1 (LRV1) can disrupt immune response, and may be the main determinant of severity of the disease; it should be investigated. To study the existence of clinical differences between patients with ML with endosymbiosis by LRV1 and. those without it. A cross-sectional cohort study with clinical evaluation, polymerase chain reaction (PCR) detection of Leishmania, species classification, and search of LRV1 was performed. Only patients with confirmed diagnosis of ML by positive PCR and with nasal mucosa injuries were included in this analysis. Out of 37 patients, 30 (81.1%) were diagnosed with Leishmania braziliensis, five (13.5%) with Leishmania guyanensis, and two (5.4%) with mixed infection of L. braziliensis and L. guyanensis. LVR1 virus was present in 26 (70.3%) of the cases. Correlation between clinical phenotype and presence of LRV1 was not observed, although the frequency of the virus is two-fold higher in mucosal lesions than that found in the literature on skin lesions in the same geographical area.